Figure 6.

Therapeutic efficacy of TCR2304-T cells in TMD8 xenograft mouse model. NOG mice were suncutaneously injected with 5×10⁶ TMD8 cells that are stably transduced with HLA*B07:02 and firefly luciferase. Tumor growth was detectable via bioluminescence imaging in all mice as early as day 2. (A) Change of tumor volume over time (error bars plotted with SEM significance analysis by two-way analysis of variance, showing difference on day 24: **p<0.01) and survival of NOG mice after treatment start. (B) Bioluminescence images of tumor-bearing mice at days 18 and 25 after treatment. Exposure: 60 s. (C) Flow cytometric analysis of systemic dissemination: proportion of TMD8 cells in tissues of tumor-bearing NOG mice. Human cells meaning sum of TMD8 lymphoma cells and human T cells. (D) Representative staining of blood samples from tumor-bearing NOG mice. Shown plots were pregated on single, viable cells.